• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·HIMS
Held by 3 Gurus
Share

Hims & Hers Health, Inc. Stocks

$ 27.77Last Updated 31.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 6.19B

$ 27.77
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.00%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.00%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.00%
Steven CohenPoint72 Asset Management, L.P.0.0%-0.00%

Latest news

27.03.2026 14:48

The obesity therapy market is changing. What smid-cap investors should know.

10.03.2026 15:34

Morning in New York: quotes remain in the turbulence zone

09.03.2026 19:09

Shares of online pharmacy Hims & Hers soared 40% amid a general sell-off. What is it?

23.02.2026 16:24

Hims & Hers to buy Australian peer Eucalyptus amid GLP-1 regulatory, legal pressure

09.02.2026 18:05

Novo shares rise: cheap copy of its drug fails to survive criticism from US regulator

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA, trading at neutral le

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of HIMS is 29.9 and suggests 7.49% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.08.2026 15:20

Warsh suggested that the Fed might reduce the number of meetings on interest rates

03.08.2026 14:41

Shares of a small-cap biotech company soared 107%. Its melanoma drug is close to approval.

03.08.2026 13:25

Morgan Stanley Expects Korean Stocks to Soar 44% After Their Worst Month Since 2008

03.08.2026 12:16

Concrete or a Presentation: How to Profit from Kazakhstan’s Investments in AI

03.08.2026 11:43

SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026